Anand Seshadri

Senior Director
15+ years of experience in industry and advisory roles
Expertise in complex transactional and transformational initiatives
Specializes in M&A
Morristown
@alvarezmarsal
LinkedIn
Copied!
Anand Seshadri is a Senior Director with Alvarez & Marsal’s Corporate Transactions Group in Morristown. He specializes in advising corporate clients through complex transactional and transformational initiatives, including M&A strategy, integrations, carve-outs and divestitures, and performance improvement.

With more than 15 years of experience spanning industry and advisory roles, Mr. Seshadri brings deep expertise across complex M&A areas, including commercial and operational diligence, cross-border integration/separation planning and execution, operating model design and performance improvement strategies. He leverages his engineering background, analytics capabilities and business acumen to deliver tailored, data-driven and holistic insights to clients across strategic, operational and financial matters from transactional to transformational initiatives.

Prior to joining A&M, Mr. Seshadri spent nine years with KPMG’s Deal Advisory & Strategy practice, advising global clients across healthcare and life sciences, financial services, and aerospace and defense sectors on due diligence, post-merger integrations and carve-outs.

Notably, Mr. Seshadri advised on the global post-merger integration for a large, multinational life sciences company in support of a $63 billion acquisition; led the post-merger integration for an EU-based life sciences company in support of an $800 million U.S. biotech acquisition; oversaw a $1 billion divestment for the generics subsidiary of a large multinational pharmaceutical company; and performed operational due diligence for an industrials company looking to acquire a market competitor.

Mr. Seshadri earned a bachelor’s degree in computer engineering from Tufts University and an MBA from Georgetown University’s McDonough School of Business. Additionally, he holds a certificate from the Artificial Intelligence in Pharma and Biotech program at MIT’s Sloan School of Management.

Insights By This Professional

This episode highlights how A&M Assist leverages AI-driven tools and A&M’s deep industry expertise to help dealmakers achieve transaction goals with unmatched speed and precision.
The JP Morgan Healthcare Conference 2025 offered a comprehensive view of the transformative trends, challenges, and opportunities shaping the biopharma and healthcare landscape. From AI to innovative biotechs, we explore the key takeaways and offer insights into how stakeholders can leverage these developments for success.
Alvarez & Marsal is proud to release the 2024 2024 Biotechnology M&A and Venture Capital Highlights Report.
A&M continues to scale its corporate transactions talent base in the U.S. as the firm meets robust client demand for its globally integrated platform.
Latest insights The latest insights from Anand Seshadri's team
Thought Leadership
Discover the state of infrastructure investment, as uncertain markets adjust to higher interest rates and cost of capital, and supply chain disruptions.
Contact me
FOLLOW & CONNECT WITH A&M